The current status of sorafenib treatment in hepatocellular carcinoma
10.3969/j.issn.1002-3070.2014.03.019
- VernacularTitle:索拉非尼治疗肝细胞癌的现状
- Author:
Bo LIANG
;
Xiao LIU
;
Dinghua YANG
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Sorafenib;
Advanced stage;
Drug resistance
- From:
Practical Oncology Journal
2014;(3):280-284
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)has high incidence rate,recurrence rate after surgecal treat-ment,as well as fatality rate in China .HCC is not sensitive to radiotherapy or chemotherapy and no effective treat-ment is available for HCC patients at advanced stage .Sorafenib is the first effective molecularly targeted drug for the treatment of HCC,which represents a milestone in the treatment of HCC .However,it also shows drug resist-ance during clinical application .Therefore,it is important to investigate the mechanism of drug resistance and its molecular markers for HCC .In this review ,we summarize the current status of the studies in these fields .
